Electrophysiological Evaluation of Ventricular Fibrillation

Published on 21/06/2015 by admin

Filed under Cardiovascular

Last modified 21/06/2015

Print this page

This article have been viewed 2168 times

Chapter 25 Electrophysiological Evaluation of Ventricular Fibrillation

Matthew Wright, Frederic Sacher, Michel Haïssaguerre

Introduction

Sudden cardiac arrest accounts for between 300,000 and 400,000 deaths in the United States alone each year. Although the underlying pathophysiology for the majority of these deaths is coronary artery disease (CAD), in autopsy studies, evidence of recent occlusive coronary thrombus is present in only up to 64% of patients.¹ Thus up to one third of all cases of unexplained sudden cardiac arrest may be primarily caused by cardiac arrhythmias, with ventricular fibrillation (VF) being the culprit arrhythmia in the majority of patients. Although secondary and primary prevention trials have demonstrated the superiority of implantable cardioverter defibrillators (ICDs) compared with antiarrhythmic drugs (AADs) in preventing death, which represents ICD therapy as the gold standard treatment for this condition, current methods of risk stratification are primarily based on the assessment of left ventricular ejection fraction (LVEF).^2,³

Moreover, approximately 10% of all deaths are unaccounted for, with autopsies revealing structurally normally hearts. Even with postmortem genetic testing, specifically for long QT syndrome (LQTS), 96% of young males who died from sudden cardiac death (SCD) had no attributable cause. Although a number of genetic syndromes that can result in VF, such as Brugada syndrome and arrhythmogenic right ventricular cardiomyopathy (ARVC), have been identified, a large population of young, otherwise healthy patients still die from idiopathic VF, which is difficult to diagnose. This chapter explores the diagnostic modalities available to the electrophysiologist to identify and risk stratify patients at risk of SCD.

Programmed Ventricular Stimulation

The use of invasive electrophysiological study (EPS) to risk stratify patients goes back almost 40 years to the observation by Wellens et al that in patients with prior myocardial infarction (MI) and ventricular tachycardia (VT), programmed ventricular stimulation could be used to induce the same VT (Figure 25-1).⁴ Although the sensitivity of programmed ventricular stimulation has been refined since its original description, a nonclinical ventricular arrhythmia is induced in approximately one third of patients.⁵ Although protocols vary among institutions, stimulation is normally performed from both the right ventricular apex and the right ventricular outflow tract (RVOT). Initially, single, double, and then triple extrastimuli are applied to a sensed ventricular beat, reducing the last extra stimulus by 20 ms each time until the effective refractory period (ERP) is reached. An eight-beat drive train is then followed by a single extrastimulus, then two and finally three extrastimuli, with the coupling interval of the last extrastimulus being decreased by 10 or 20 ms until the ERP is reached for the first extrastimulus. Typically, 600-ms and 400-ms drive trains are used. Most operators stop extrastimuli at a coupling interval of 180 to 200 ms because with shorter coupling intervals, the specificity of the test is reduced and polymorphic VT and VF occur more frequently.⁶ However, recent work suggests that patients with VT of a cycle length 200 to 250 ms are at high risk of a subsequent event and that this should not be taken as a nonsignificant event in patients with ischemic cardiomyopathy (Table 25-1).⁷

FIGURE 25-1 The initial description of induction of ventricular tachycardia with programmed ventricular stimulation. Initiation of a tachycardia by a single right ventricular premature beat (premature beat interval of 280 ms) during regular driving of the right ventricle (basic cycle length of 580 ms). No bundle of His electrogram precedes the ventricular complex. As shown in the right atrial lead, the first ventricular complex during the tachycardia is followed by retrograde atrial activation; thereafter 2 : 1 ventriculoatrial conduction is present during the tachycardia. The QRS complex configuration during the tachycardia suggests a left ventricular origin.

(From Wellens HJ, Schuilenburg RM, Durrer D: Electrical stimulation of the heart in patients with ventricular tachycardia, Circulation 46:216–226, 1972.)

Ischemic Heart Disease

The Multicenter Unsustained Tachycardia Trial (MUSTT) was a multi-center prospective study that enrolled 2202 patients with significant CAD, reduced LVEF (<40%), and nonsustained VT and subjected patients to programmed ventricular stimulation.⁸ VT was induced in just over one third of patients. These patients were then randomized to either no AAD therapy or AAD therapy guided by repeated stimulation. If VT remained inducible despite AAD therapy, an ICD was implanted. Patients in whom sustained monomorphic VT was induced were monitored by a registry. Although this study confirmed that patients with inducible VT off AADs had a higher rate of arrhythmic events over the following 5 years compared with those without inducible VT (36% vs. 24%; P = .005), the event rate in patients without inducible VT at the time of invasive EPS was not insignificant (Figure 25-2).⁹

FIGURE 25-2 The role of invasive electrophysiological testing in patients with ischemic cardiomyopathy from the Multicenter Unsustained Tachycardia Trial (MUSTT). Shown are Kaplan-Meier estimates of the rates of cardiac arrest or death from arrhythmia in the registry patients and the patients with inducible ventricular tachyarrhythmias who were not assigned to antiarrhythmic therapy.

(From Buxton AE, Lee KL, DiCarlo L, et al: Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators, N Engl J Med 342:1937–1945, 2000.)

As just stated, it is not uncommon to induce polymorphic VT and VF at shorter extrastimulus coupling intervals and with multiple extrastimuli. In the MUSTT trial, induction of polymorphic VT or VF was considered positive only if this occurred with up to two extrastimuli. In a retrospective analysis of the Multicentre Automatic Defibrillator Trial II (MADIT-II), for which patients had to have an LVEF less than 30% and a prior MI, programmed ventricular stimulation was prognostic only when a positive result was taken—that is, not when polymorphic VT or VF had been induced with aggressive pacing.^9,¹⁰ Although many studies were performed on acute arrhythmia suppression with AADs, the long-term use of AADs to prevent VT and VF has been disappointing, and it is now common to implant ICDs in patients at risk. However, this is mainly based on the patient’s LVEF, not on invasive testing.^8,^9,^11,¹²

Current guidance for the use of programmed ventricular stimulation is based largely on the MADIT-I and MADIT-II trials and the results of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).¹¹^–¹³ In the United Kingdom, the National Institute for Health and Clinical Excellence updated the guidelines for ICD implantation, which are used in other health care systems throughout the world. These evidence-based guidelines suggest that the role of programmed ventricular stimulation in the decision to implant an ICD is restricted to patients with a previous MI (>6 weeks), an LVEF of 30% to 35%, a lack of New York Heart Association (NYHA) class IV symptoms, and nonsustained VT on monitoring. These criteria were derived from the enrollment criteria to the MADIT-I study. Patients who were enrolled in the MADIT-II study with an LVEF less than 30% did not need to undergo invasive EPS. Although it appears that programmed ventricular stimulation has quite a narrow indication in the decision of when to implant an ICD, it still remains a useful tool. The absolute benefit from ICD implantation in the MADIT trial was 12% per year in which patients had to have a “positive” test result compared with a more modest absolute benefit of approximately 3% and 1.5% per year, respectively, in the MADIT-II and SCD-HeFT populations, in whom programmed ventricular stimulation was not used to determine ICD implantation.

On the basis of the MUSTT trial results, patients with clinically significant CAD and an LVEF of 30% to 40% and nonsustained VT would also benefit from ICDs if they had a positive programmed ventricular stimulation test result.^8,⁹ Again, a large absolute benefit was demonstrated in this patient population, although for most patients the clinically significant CAD was a prior MI.

A recent study has shown that performing programmed ventricular stimulation may be beneficial when patients presented within the first few weeks after an MI and with an LVEF of less than 40% (Figure 25-3).¹⁴ ICD implantation is not routinely considered in these patients as a result of the Defibrillator in Acute Myocardial Infarction Trial (DINAMIT), which demonstrated that patients with an ICD implanted within the first month of an MI with an LVEF of less than 35% and depressed autonomic function, as assessed by heart rate variability, actually had a worse outcome.¹⁵ Although fewer patients died of arrhythmic events, the rate of nonarrhythmic death was substantially high. These data, as well as those from the Immediate Risk Stratification Improves Survival (IRIS) trial, which also investigated early implantation of an ICD in high-risk patients (as assessed by reduced LVEF <40%, depressed autonomic function, or nonsustained VT on Holter monitoring), demonstrated no absolute mortality benefit from implantation.¹⁴ This has led to the current situation in which high-risk patients do not receive ICDs after an MI.^16,¹⁷

FIGURE 25-3 The role of invasive electrophysiological study after myocardial infarction. Shown are Kaplan-Meier curves for sudden death or ventricular tachycardia or ventricular fibrillation (VT or VF) stratified by those with inducible VT or VF at invasive electrophysiological (EP) study 9 days after successful revascularization. HR, Hazard ratio.

(From Kumar S, Sivagangabalan G, Zaman S, et al: Electrophysiology-guided defibrillator implantation early after ST-elevation myocardial infarction, Heart Rhythm 7:1589–1597, 2010.)

In the latest study, however, programmed ventricular stimulation has been used to risk stratify patients, in contrast to the noninvasive measures in the IRIS and DINAMIT studies. In the study by Kumar et al, patients with previous MI and an LVEF less than 40% had programmed ventricular stimulation at an average of 9 days after the acute event. An ICD was implanted in patients in whom VT could be induced with a cycle length greater than 200 ms with up to four extrastimuli. In this study, patients with a positive test result were at a substantially higher risk (hazard ratio [HR], 14.3) compared with those who had a negative test result, and implantation of an ICD seemed to confer benefit in this patient population. An important distinction in this study compared with the earlier DINAMIT and IRIS trials was that patients had to have been successfully revascularized before enrollment.

The results of MUSTT, taken together with the more recent work on early programmed ventricular stimulation after successful revascularization, suggest that programmed ventricular stimulation is a useful tool in risk stratifying patients with a reduced ejection fraction after MI (Table 25-2). Compared with signal-averaged electrocardiograms (ECGs) and LVEF, programmed ventricular stimulation is the best predictor of spontaneous ventricular arrhythmia late after MI in patients with reduced ejection fraction.^18,¹⁹

Table 25-2 Use of Invasive Electrophysiological Testing after Myocardial Infarction

Idiopathic Dilated Cardiomyopathy

The role of programmed ventricular stimulation in the risk assessment of patients with idiopathic dilated cardiomyopathy (IDCM) is not well studied. Approximately 50% of patients with IDCM will have SCD caused by ventricular arrhythmia as opposed to progressive heart failure.²⁰ Impairment of left ventricular function alone does not appear to be a specific marker for risk.^11,^21,²² In the Cardiomyopathy Trial (CAT), 104 patients with IDCM and an LVEF less than 30% were randomized to either medical or ICD therapy.²³ This trial had a very low rate of β-blocker use, which makes interpretation more difficult in the contemporary era. Despite this, overall mortality was very low, and the trial was stopped early because of futility.

Buy Membership for Cardiovascular Category to continue reading. Learn more here